Group 1 - Canaan Technology's stock price dropped by 5.1% to 5.40 CNY per share, with a trading volume of 1.33 billion CNY and a turnover rate of 5.13%, resulting in a total market capitalization of 2.688 billion CNY [1] - The company, established on December 15, 2008, and listed on December 31, 2014, specializes in the research, production, and sales of solid preparation equipment [1] - The revenue composition of Canaan Technology includes 58.32% from oral solid preparation equipment, 24.51% from biological and sterile preparation water equipment and liquid system engineering, 13.58% from other equipment series, 2.08% from intelligent warehousing logistics systems and equipment, and 1.51% from other supplementary sources [1] Group 2 - Noan Fund's Noan Multi-Strategy Mixed A (320016) entered the top ten circulating shareholders of Canaan Technology in the second quarter, holding 2.031 million shares, which is 0.43% of the circulating shares [2] - The estimated floating loss for Noan Multi-Strategy Mixed A today is approximately 589,000 CNY [2] - The fund, established on August 9, 2011, has a latest scale of 1.399 billion CNY, with a year-to-date return of 66.58%, ranking 172 out of 8194 in its category, and a one-year return of 133.99%, ranking 58 out of 7963 [2]

报告期内，公司研发投入8075.57万元占营业收入的5.84%。截至报告期末，公司累计获得国家授权专利 1112项，其中发明专利142项(美国专利6项)。同时，公司持续加强与浙江大学、同济大学等科研院校的 合作，为公司的持续发展提供了有力的技术支撑。 展望未来，公司表示将继续围绕"固体制剂智能工厂整体解决方案供应商"和大健康产业战略布局，深耕 制药装备市场，目标成为国际主流的制药装备智能工厂整线解决方案供应商，同时向大健康产业纵深推 进。此外，公司还将积极推动专用机器人业务的研发创新，不断优化产品体系，拓宽应用场景，持续提 升公司综合竞争力，为业绩增长注入新动力（300152）。(厉平) 4月19日，迦南科技（300412）(300412.SZ)发布2024年年报。报告显示，公司2024年营业收入为13.83亿 元，同比增长32.09%，创历史新高；归母净利润为3626.70万元，同比增长254.77%；扣非归母净利润为 2752.14万元，同比增长173.06%；较上年扭亏为盈。 报告显示，公司是国内知名的口服固体制剂智能工厂整体解决方案供应商。具体业务板块可细分为口服 固体制剂设备及智能工厂业务、生物及无 ...